# A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

> **NCT03241550** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Hematological Malignancy

## Interventions

- **DRUG:** isavuconazonium sulfate - intravenous
- **DRUG:** isavuconazonium sulfate - oral

## Key facts

- **NCT ID:** NCT03241550
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-02
- **Primary completion:** 2019-07-05
- **Final completion:** 2019-07-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241550, "A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03241550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*